eXoZymes (EXOZ) has launched BioClick, an innovative enzyme engineering initiative supported by a $300,000 NIH grant. The project focuses on enhancing group transfer reactions, particularly prenylation, to improve drug development and biomanufacturing processes. BioClick is the third generation of enzyme engineering, following directed evolution and rational protein design, and integrates artificial intelligence and high-throughput screening to test thousands of enzyme variations simultaneously using mass spectrometry and advanced data analysis algorithms. This technology aims to accelerate the development of new and existing drugs by creating previously inaccessible small molecules. The BioClick platform is designed to improve drug compound functionality and effectiveness through precise molecular modifications.
The technology also introduces a new high-throughput screening capability, allowing researchers to test thousands of enzyme variations in parallel. This will reduce the time and cost required to develop the exozyme pathway that will produce a new or better drug. eXoZymes claims that their BioClick platform has the potential to introduce new drugs and improve existing ones, making it a promising development in the field of drug development and biomanufacturing.